Abcam plc. (7/2/18). "Press Release: Abcam Merck Collaboration Produces New PD-L1 Antibody for Immuno-Oncology Research". Cambridge.

	Organisation	Abcam plc (AIM: ABC, Nasdaq: ABCM)
	Group	Abcam (Group)
	Organisation 2	Merck KGaA
	Group	Merck (DE) (Group)
	Product	research antibody
	Product 2	cancer immunotherapy (immuno-oncology, I-O)
	Index term 2	Abcam–Instinctif Partners: public relations, 201807 service existent by Instinctif
	Person	Baker, John (Abcam 201807 SVP Portfolio + Business Development)
	Person 2	Trowbridge, Lynne (Abcam 201911 VP External Communications formerly Instinctif + College Hill Life Sciences)

Clone 73-10 now available to the global research community

Abcam, a global innovator in life science reagents and tools today announced the commercial launch of the new anti-PD-L1 antibody clone MKP1A07310 (clone 73-10) developed in collaboration with Merck KGaA, Darmstadt, Germany.

Developed by Abcam for use by Merck as an analytical antibody to support Merck’s therapeutic programme several years ago, this new clone has been created by Abcam’s in-house antibody engineers, who specialise in the discovery and development of challenging antibodies. The antibody is important in assessing the expression of PD-L1 in tumors from patients who might be able to benefit from PD-1/PD-L1 checkpoint immunotherapy.

John Baker, SVP Portfolio and Business Development, Abcam said: “Collaborations with industry partners are an important part of Abcam’s strategy to provide the best tools to all researchers world-wide. By working with Merck we are able to make available this important antibody at scale to help scientists accelerate their research, and expand understanding of the role of immune checkpoint inhibitors as cancer therapeutics.”

Clone 73-10 is an important addition to Abcam’s range of PD-1/PD-L1 immune checkpoint antibodies and is available via the Abcam website. To find out more please visit www.abcam.com/pdl1-ab-73-10.

About Abcam

As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam’s ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

Two-thirds of the world’s 750,000 life science researchers use Abcam’s affinity binders, reagents, biomarkers and assays and the Company’s products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences.

By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Abcam’s eleven locations are in the world’s leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 100 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).

Contacts

Abcam
Francesca Axe
+44 1223 696000

Media enquiries
Dr. Lynne Trowbridge / Tim Watson, Instinctif Partners
+44 20 7866 7861
abcam@instinctif.com

Record changed: 2023-06-05